Home / Stocks / Ennature Bio Pharma Ltd
ENNATURE Updated about 8 hours ago

Ennature Bio Pharma Ltd Share Price

NSE closing price and which mutual funds hold this stock

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 19 Nov 2026

₹178.4

Change

-17.85 (-9.1%)

Open

₹191.95

Prev. Close

₹196.25

Day High

₹198.45

Day Low

₹175.5

Volume Analysis

Traded

157,879

Delivered

85,699

Delivery %

54.28%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹215.69 ₹207.07 ₹192.74 ₹184.12 ₹169.79 ₹161.17 ₹146.84
Fibonacci ₹207.07 ₹198.3 ₹192.89 ₹184.12 ₹175.35 ₹169.94 ₹161.17
Camarilla ₹184.71 ₹182.61 ₹180.5 ₹184.12 ₹176.3 ₹174.19 ₹172.09

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-12.78%

1 Month

—

3 Months

—

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Ennature Bio Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Corporate Governance (100/100), while Institutional Ownership (10/100) is the weakest area to weigh before deciding.

TopFund Score — Fundamentals Quality

52/100 — Average

Data confidence: 55/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Corporate Governance

100

Institutional Ownership

10

Liquidity

41

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Board designated five executives as senior management personnel effective 12 November 2026.

Board approved new Articles of Association on 12 November 2026, subject to shareholder and regulatory approvals.

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

  Nov 2026
Public 33.33%
Promoters 59.63%
FII 2.44%
DII 4.61%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ennature Bio Pharma Ltd (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Ennature Bio Pharma Ltd?

Frequently Asked Questions about Ennature Bio Pharma Ltd

Community Sentiment

What are other investors saying about Ennature Bio Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.